Washington, DC 20477, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: September 11, 2000.

#### **Bob Sargis**,

Reports Clearance Officer. [FR Doc. 00–23709 Filed 9–14–00; 8:45 am] BILLING CODE 4184–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

## Request for Nominations for Nonvoting Members of Industry Interests on Public Advisory Committees; Extension of Nomination Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of nomination period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending the nomination period for nonvoting representatives of industry interests to serve on public advisory committees under the purview of the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). This request for nominations was announced in the Federal Register of August 16, 2000 (65 FR 49990). FDA has been asked to extend the nominations period to allow additional time for the submission of nominations. Note also that the street address for the CBER contact person has been changed. DATES: Nominations should be received

by October 16, 2000.

**ADDRESSES:** All nominations for representatives should be sent to William Freas or John M. Treacy (addresses below).

#### FOR FURTHER INFORMATION CONTACT:

- Regarding representatives of industry interests for CBER advisory committees: William Freas, Scientific Advisors and Consultants Staff (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–0314, FAX: 301–827– 0294, or e-mail: FREAS@CBER.FDA.GOV.
- Regarding representatives of industry interests for CDER advisory committees: John M. Treacy, Advisors and Consultants Staff (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 7001, FAX: 301–827–6776, or email: TREACY@CDER.FDA.GOV.

Dated: September 12, 2000.

#### Linda A, Suydam,

Senior Associate Commissioner.

[FR Doc. 00–23880 Filed 9–13–00; 1:36 pm] BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

#### Antiviral Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

# **ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Antiviral Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on October 16, 2000, 8:30 a.m. to 5 p.m.

*Location:* Marriott Washingtonian Center, the Ballrooms, 9751 Washingtonian Blvd., Gaithersburg, MD.

*Contact Person:* Nancy Chamberlin or Beverly O'Neil, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301–827–7001, or by e-mail: CHAMBERLINN@CDER.FDA.GOV, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the use of surrogate markers in the early development of immunomodulatory agents for the treatment of patients with human immunodeficiency virus (HIV).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 2, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. to 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 2, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 23, 2000.

# Linda A. Suydam,

Senior Associate Commissioner. [FR Doc. 00–23798 Filed 9–14–00; 8:45 am] BILLING CODE 4160–01–F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. 00N-1394]

#### Medical Devices; CLIA Waiver Criteria; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending to October 16, 2000, the comment period for the notice of a public workshop that appeared in the Federal Register of July 21, 2000 (65 FR 45384). That notice announced FDA's intention to review the criteria used to determine whether specific laboratory tests are waived from certain requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This extension of the comment period is intended to allow interested persons additional time to submit comments on the CLIA waiver criteria.

**DATES:** Submit written comments by October 16, 2000.

**ADDRESSES:** Submit written comments on the notice of public workshop to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

# FOR FURTHER INFORMATION CONTACT:

Clara A. Sliva, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-827-0496

#### SUPPLEMENTARY INFORMATION:

#### I. Extension of Comment Period

In the Federal Register of July 21, 2000 (65 FR 45384), FDA published a notice of a public workshop to review the criteria used to determine whether specific laboratory tests are waived from certain requirements of the CLIA. FDA is soliciting comments from interested persons concerning the review of criteria and the process that the agency should use to determine when a particular test is waived. CLIA specifies that laboratory requirements be based on the complexity of the tests performed and establishes criteria for categorizing a test as waived. Responsibility for determining whether a particular test is waived was transferred from the Centers for Disease Control and Prevention (CDC) to FDA on January 31, 2000.

FDA received several requests to extend the comment period for an additional month to allow adequate time to respond. In response to the requests. FDA is extending the comment period until October 16, 2000.

# **II. Comments**

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding this notice by October 16, 2000. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: September 12, 2000.

# William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00-23881 Filed 9-13-00; 1:36 pm] BILLING CODE 4160-01-E

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Health Care Financing Administration**

[Document Identifier: HCFA-10005]

## Agency Information Collection Activities: Submission for OMB **Review; Comment Request**

**AGENCY:** Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Request: New collection; Title of Information Collection: Ticket to Work and Work Incentives: Medicaid Infrastructure Grants; HCFA Form Number: HCFA-10005 (OMB approval #: 0938-NEW); Use: Section 203 of the Ticket to Work and Work Incentives Act of 1999 provides for the establishment of a grants program for states that build infrastructures designed to support people with disabilities. State agencies will be applying for these grants; Frequency: Annually; Affected Public: State, local or tribal govt.; Number of Respondents: 56; Total Annual Responses: 56; Total Annual Burden Hours: 5,600.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at http://www.hcfa.gov/ regs/prdact95.htm, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to

the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: September 8, 2000.

#### John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards. [FR Doc. 00-23707 Filed 9-14-00; 8:45 am] BILLING CODE 4120-03-P

# DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

#### **Health Resources and Services** Administration

# Advisory Committee; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of October 2000.

Name: Advisory Committee on Infant Mortality (ACIM)

Date and Time: October 5, 2000; 9 a.m.-5 p.m.; October 6, 2000; 8:30 a.m.-3 p.m.

Place: Holiday Inn Washington, D.C. on the Hill, 415 New Jersey Avenue, NW., Washington, DC 20001, (202) 638-1616.

The meeting is open to the public.

Purpose: The Committee provides advice and recommendations to the Secretary of Health and Human Services on the following: Department programs which are directed at reducing infant mortality and improving the health status of pregnant women and infants; factors affecting the continuum of care with respect to maternal and child health care, including outcomes following childbirth; factors determining the length of hospital stay following childbirth; strategies to coordinate the variety of Federal, State, and local and private programs and efforts that are designed to deal with the health and social problems impacting on infant mortality; and the implementation of the Healthy Start initiative and infant mortality objectives from Healthy People 2010.

*Agenda:* Topics that will be discussed include: Early Postpartum Discharge; Low-Birth Weight; Disparities in Infant Mortality; and the Healthy Start Program.

Anyone requiring information regarding the Committee should contact Peter C. van Dyck, M.D., M.P.H., Executive Secretary, ACIM, Health Resources and Services Administration (HRSA), Room 18-05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2170.

Individuals who are interested in attending any portion of the meeting or who have questions regarding the meeting should contact Ms. Kerry P. Nesseler, HRSA, Maternal and Child Health Bureau, Telephone (301) 443-2170.